AffyMax Company Profile: Stock Performance & Earnings

AffyMax Overview

Founded
2001

Status
Public

Employees
72

Stock Symbol
AFFY

Share Price
$0.02
(As of Thursday Closing)

AffyMax General Information

Description

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.

Contact Information

Website

www.affymax.com

Ownership Status

Publicly Held

Financing Status

Formerly VC-backed

Primary Industry

Pharmaceuticals

Other Industries

Drug Discovery

Stock Exchange

PINX

Primary Office

600 Fifth Avenue
2nd Floor
New York, NY 10020
United States

+1 (650) 000-0000



Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

AffyMax Stock Performance

(As of Thursday Closing)

Stock Price	Previous Close	52 wk Range	Market Cap	Shares	Average Volume	EPS
$0.02	$0.03	$0.01 - $0.06			30.4K

AffyMax Financials Summary

In Thousands, USD	TTM 30-Jun-2014	FY 2013 31-Dec-2013	FY 2012 31-Dec-2012	FY 2011 31-Dec-2011
EV	(1,051)	22,390	636,650	120,931
Revenue	42	1,369	94,370	47,720
EBITDA	2,694	(14,316)	(90,086)	(59,209)
Net Income	2,694	(14,424)	(93,412)	(61,367)
Total Assets	5,384	7,443	118,217	118,995
Total Debt	0	0	8,844	0

Public Fundamental Data provided by Morningstar, Inc. disclaimer

AffyMax Valuation & Funding

Deal Type	Date	Amount	Valuation/ EBITDA	Post-Val	Status	Debt

This information is available in the PitchBook Platform. To explore AffyMax‘s full profile, request access.

Request a free trial

AffyMax Comparisons

Description

Primary
Industry

HQ Location

Employees

Total Raised

Post Valuation

Last Financing Details

Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for

Pharmaceuticals

New York, NY

72 As of 2015

00000

0.00 0000-00-00

000000000 00000

000000 (

t nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt

0000 000000000

New York, NY

0 As of 0000

00000

0000000000 00000

000000 0

uptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proi

0000 000000000

Toronto, Canada

0 As of 0000

000.00

000000000 000.00

Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

AffyMax Competitors (13)

Company Name	Financing Status	Location	Employees	Total Raised	Last Financing Date/Type	Last Financing Amount
Akelos (Drug Discovery)	Angel-Backed	New York, NY	0	00000	0000000000	00000
000000 00000000000	Corporation	Toronto, Canada	0	000.00	000000000	000.00
0000	Venture Capital-Backed	San Diego, CA	0	00000	0000000000 0	00000
0000000 0000000000	Corporation	Guilford, CT		00.00	000000000	00.00
000000 000000000	Formerly PE-Backed	Germantown, MD	0	000.00	000000000	000.00

You’re viewing 5 of 13 competitors. Get the full list »

AffyMax Executive Team (30)

Name	Title	Board Seat	Contact Info
Mark Thompson	Chief Financial Officer, Finance
Grace Shin JD	General Counsel
Christine Conroy	Senior Vice President, Regulatory Affairs and Quality Assurance
Michael Holfinger Ph.D	Vice President
Anne-Marie Duliege MD	Chief Medical Officer